Case Law
EU Commission
- Sintesi della relazione relativa all’indagine sul settore farmaceutico
- Commission Decision of 19.06.2013- Case AT.39226 – LUNDBECK
Antitrust
- Commission Decision of 8.12.2010 – Case AT.39510 – ONP
- Commission Decision of 10.12.2013 – Case AT.39685 – FENTANYL
- Commission Decision of 15.06.2005 – Case COMP_A. 37.507_F3 – AstraZeneca
- Commission Decision of 26.11.2020 – Case AT.39686-CEPHALON
- Commission Decision of 28.01.2021- Case AT.40394 – Aspen
- Commission Decision of 30.09.2016- Case AT.39612 – Perindopril (Servier)
- European Commission – Press release Antitrust_ Commission opens investigation into possible anticompetitive disparagement by Vifor Pharma of iron medicine
- Relazione della Commissione europea – Applicazione delle norme sulla concorrenza nel settore farmaceutico 2009-2017
Merger
- Ritiro di notifica di concentrazione (Caso M.9547 — Johnson & Johnson_Tachosil)ù
- Case M.9331 — DANAHER _ GE HEALTHCARE LIFE SCIENCES BIOPHARMA
- Case M.9461 – ABBVIE _ ALLERGAN
- Case M.9517 – MYLAN _ UPJOHN
- Case M.9554 – ELANCO ANIMAL HEALTH _ BAYER ANIMAL HEALTH DIVISION
- Case No COMP_M.6410 – UTC_ GOODRICH
- Case No COMP_M.7435 – MERCK_ SIGMA-ALDRICH
- Competition_ The European Commission forms a Multilateral Working Group with leading competition authorities to exchange best practices on pharmaceutical mergers
- EU MERGER CONTROL Interventions from December 2019
- Mergers_ Commission opens in-depth investigation into proposed acquisition of GRAIL by Illumina
- Mergers_ The Commission adopts a Statement of Objections in view of adopting interim measures following Illumina’s early acquisition of GRAIL
- Mergers__Commission_alleges_Merck_and_Sigma-Aldrich__General_Electric__and_Canon_breached_EU_merger_procedural_rules
- Mergers__Commission_approves_acquisition_of_medical_device_company_Synthes_by_Johnson__amp__Johnson
- Mergers__Commission_approves_acquisition_of_Sigma-Aldrich_by_Merck__subject_to_conditions.
European Union Court of Justice
- EUCJ – Judgement of 8.07.2021 – Case C-178_20 – Pharma Expressz
- EUCJ – Judgement of 8.09.2016 – Case T-472_13 – Lundbeck
- EUCJ – Judgement of 11.04.2013 – Case C-535_11 – Novartis – Apozyt
- EUCJ – Judgement of 21.11.2018 – Case C-29_17 – Novartis – Roche
- EUCJ – Judgement of 23.01.2018 – Case C-179_16 – Avastin Lucentis
- EUCJ – Judgement of 25.03.2021 – Case C-591_16 P – Lundbeck
- EUCJ – Judgement of 30.01.2020 – Case C-307_18 – Generics (UK) Ltd.
- The Court of Justice and Healthcare
National Court & Competition Authorities
- AGCM – Provvedimento n. 5486 ( IC14 ) SETTORE FARMACEUTICO
- AGCM- Provvedimento del 5 marzo 2014 – I760 – Roche – Novartis
- CMA – Decision of 7.12.2016 – Case CE_9742-13 – Pfizer – Flynn
- CMA – Decision of 12.2.2016 – Paroxetine – Case CE-9531_11
- Cons. Stato, sez. VI., sent. 19 luglio 2019, n. 4990 – Avastin – Lucentis
- Corte Costituzionale sentenza 8_2011
- Corte Costituzionale sentenza 151_2014
- COUR D’APPEL DE PARIS Pôle 5 – Chambre 15 ORDONNANCE DU 12 Mai 2021 – Avastin Lucentis
- Décision n° 20-D-11 du 9 septembre 2020 relative à des pratiques mises en œuvre dans le secteur du traitement de la dégénérescence maculaire liée à l’âge (DMLA) – Avastin Lucentis
- Ordinanza di rinvio del CDS a Corte Ue
- Provvedimento AGCM 24823
- Sentenz. Tar lazio 12168_2014 (NV e Roche vs agcm)sentenza CDS 4538_2014 Veneto vs NovSentenza Tar Lazio 12365 Nv vs Aifa